News
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained increase in CSF neurofilament light chain (Nf-L) protein observed through day 85 VO659 is...
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with...
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ -- Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
Sharing RDD Colours in Leiden Science Park
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease
Leiden, The Netherlands, 29 July 2021 - VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 29 June 2021 - VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development...
VICO & BioPartner Light Up on Rare Disease Day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their...
European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 10 February 2021 - VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained increase in CSF neurofilament light chain (Nf-L) protein observed through day 85 VO659 is...
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with...
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ -- Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
Sharing RDD Colours in Leiden Science Park
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease
Leiden, The Netherlands, 29 July 2021 - VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 29 June 2021 - VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development...
VICO & BioPartner Light Up on Rare Disease Day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their...
European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 10 February 2021 - VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
